Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239528 | 0.86 | ALDH1A1 (0.43) | FAAHELANEALDH1A1POLBPTGS1 | |
| SCHEMBL10154728 | 0.81 | FAAH (0.41) | FAAHMAPK1CPB2 | |
| SCHEMBL10121266 | 0.80 | NPC1 (0.44) | ALDH1A1POLB | |
| SCHEMBL20239427 | 0.79 | NPC1 (0.44) | ALDH1A1POLBL3MBTL1MAPK1MAPT | |
| SCHEMBL31130115 | 0.78 | ERCC5 (0.41) | ELANEALDH1A1PTGS1PTGS2LMNA | |
| SCHEMBL1706369 | 0.76 | FAAH (0.41) | FAAHALDH1A1POLB | |
| SCHEMBL21333330 | 0.74 | FAAH (0.52) | FAAHELANELMNATSHRMAPT | |
| SCHEMBL19534978 | 0.72 | ALDH1A1 (0.41) | ELANEALDH1A1POLBL3MBTL1PTGS1 | |
| SCHEMBL16921566 | 0.71 | NPSR1 (0.47) | FAAHALDH1A1L3MBTL1LMNANFKB1 | |
| SCHEMBL12125440 | 0.71 | MTNR1A (0.37) | ELANEPOLBL3MBTL1CCNE2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-110114351-B | Heterocyclic inhibitors of MCT4 | 维托尔股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3551625-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | FAAH 3554/4885ELANE 1694/4885ALDH1A1 665/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | FAAH 3554/4885ELANE 1694/4885ALDH1A1 665/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | FAAH 3554/4885ELANE 1694/4885ALDH1A1 665/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | FAAH 3554/4885ELANE 1694/4885ALDH1A1 665/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | FAAH 3554/4885ELANE 1694/4885ALDH1A1 665/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | FAAH 3371/4885ELANE 3628/4885ALDH1A1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.